Quantcast
Last updated on April 18, 2014 at 7:15 EDT

Latest Drugs for Neglected Diseases Initiative Stories

2013-12-05 14:04:16

Report provides real and estimated costs of repurposing drugs and new chemical entities, evoking the lessons learned based on alternative pathways and partnerships Today, at a scientific meeting at Institut Pasteur, France, entitled ‘Best Science for the Most Neglected: Where Do We Stand Ten Years On?’, co-organized with Institut Pasteur and MSF and in collaboration with PLOS, the Drugs for Neglected Diseases initiative (DNDi) marks its 10-year anniversary by issuing a report that...

2013-11-15 10:43:35

First placebo-controlled study in adults with Chagas disease highlights urgent need to scale up treatment for millions of patients at risk According to results of the first-ever Phase 2 clinical trial in Bolivia, conducted by the Drugs for Neglected Diseases initiative (DNDi), the experimental drug candidate E1224 showed good safety and was effective at clearing the parasite that causes Chagas disease, but had little to no sustained efficacy one year after treatment as a single medication....

2013-11-01 11:22:32

Inaction has jeopardized the health and economic well-being of millions A leading cause of heart disease remains overlooked in North America's most impoverished communities, researchers said today in an editorial published in PLOS Neglected Tropical Diseases. Chagas disease has rendered a heavy health and economic toll, yet insufficient political and medical support for gathering specific data, providing diagnosis and treatment, and developing new tools has impeded much-needed...

2013-02-26 16:26:27

- DNDi, in the words of the jury, has "developed and delivered new, effective and affordable treatments for poverty related diseases." MADRID, Feb. 26, 2013 /PRNewswire/ -- The fifth annual BBVA Foundation Frontiers of Knowledge Award in the Development Cooperation category goes to the Drugs for Neglected Diseases initiative (DNDi) for "developing and delivering new, effective and affordable treatments for poverty related diseases including Chagas disease, sleeping sickness,...

2012-08-20 23:01:30

Dr. James Orbinski, a globally recognized humanitarian practitioner and advocate, as well as a leading scholar in global health, has been appointed as Director of the Africa Initiative at The Centre for International Governance Innovation. Waterloo, Ontario (PRWEB) August 20, 2012 Dr. James Orbinski has been appointed Director of the Africa Initiative, effective September 2012, The Centre for International Governance Innovation (CIGI) announced today. He also will be a senior adviser to...

2012-05-21 23:54:22

DNDi welcomes World Health Organization expert recommendations to begin negotiations for an R&D convention at the World Health Assembly After a decade-long process of analysis and deliberations on ways to better address the health needs of developing countries, a recently released report of the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG) will be discussed this week at the 65th World Health Assembly (agenda item 13.14). The Drugs for...

2012-04-09 09:44:14

Global Health R&D Forum convenes global health advocates, researchers and industry leaders New York voters recognize the importance of global health research and are concerned about the United States' ability to compete globally, according to a new poll commissioned by Research!America, yet an overwhelming majority (93%) of those polled don't know where global health research is conducted in their own state. The majority of New Yorkers (64%) think that New York residents should be...

2012-01-30 08:35:25

On the occasion of today's high-level event in London, 'Uniting to Combat Neglected Tropical Diseases,' organized in support of the new World Health Organization (WHO) Neglected Tropical Disease (NTD) 2020 Roadmap, the Drugs for Neglected Diseases initiative (DNDi) welcomes the commitments from various partners and emphasizes that filling the major gaps in research and development (R&D) for new treatment and diagnostic tools is key to effectively support elimination or control of targeted...

2012-01-30 05:05:00

GENEVA, Jan. 30, 2012 /PRNewswire/ -- The Drugs for Neglected Diseases initiative (DNDi) and Abbott (NYSE: ABT) have signed a four-year joint research and non-exclusive licensing agreement to undertake research on new treatments for several of the world's most neglected tropical diseases, including Chagas disease, helminth infections, leishmaniasis and sleeping sickness. Through this collaboration, DNDi and Abbott scientists will focus initial efforts on discovering and advancing novel...

2011-12-01 19:17:50

Less than one-quarter (23%) of children with HIV/AIDS who need treatment are getting it, according to a report released by the World Health Organization (WHO) on the occasion of World AIDS Day (1 December 2011). Although treatment coverage for adults has been steadily climbing and has now reached approximately half of those in need, coverage for children is lagging far behind, highlighted the Drugs for Neglected Diseases initiative (DNDi), a non-profit research and development organization...